Health
EOM Pharmaceutical Holdings Reports FDA Clearance of an IND for a Clinical Trial in Cachectic Cancer Patients
MONTVALE, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”, the “Company”) an innovative clinical-stage biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and retinal diseases, is pleased to announce that the FDA has cleared its Investigational New Drug (IND) application to conduct a three-month Phase 2a clinical study of EOM613 in cachectic cancer patients. “EOM has designed a Phase 2a clinical tri
About this update from Eom Pharmaceutical Holdings Inc.
[{"type":"text","content":"MONTVALE, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”, the “Company”) an innovative clinical-stage biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and retinal diseases, is pleased to announce that the FDA has cleared its Investigational New Drug (IND) application to conduct a three-month Phase 2a clinical study of EOM613 in cachectic cancer patients.","length":458,"tagName":"p"},{"type":"text","content":"“EOM has designed a Phase 2a clinical trial for the treatment of cancer cachexia patients who currently have no approved therapies,” stated Shalom Z. Hirschman, MD, Chief Medical Officer of EOM. “In previous clinical trials in cachectic AIDS patients and COVID-19 patients, EOM613 treatment was well-tolerated, even in extremely sick patients. A broad-spectrum immune regulating agent that regulates pro-and anti-inflammatory cytokines in patients without the risk of severe side effects could prove to be beneficial in the treatment of cancer cachexia, which is largely a cytokine-driven process. We are pleased to continue to explore the potential use of EOM613 in treating cancer cachexia patients given the promising results in the early exploratory trial in Canada.”","length":771,"tagName":"p"},{"type":"text","content":"Cancer cachexia is a highly debilitating wasting syndrome exhibited by a large percentage of patients with advanced malignancies, marked by weight loss, muscular weakness, anorexia, anemia, and hypoproteinemia. Cachectic patients often are debilitated and unable to tolerate rounds of chemotherapy. Cancer cachexia is largely an inflammatory process in the body, wherein pro-inflammatory cytokines, including Interleukin-6, TNF-alpha, Interleukin-1-beta and Interferon-gamma, are released within the body. Cytokines induce protein degradation, leading to a loss of muscle mass and weight and hypermetabolism. They also interfere with hypothalamic regulation, leading to reduced food intake in patients with advanced cancers. There is currently no FDA-approved therapy for cancer cachexia.","length":788,"tagName":"p"},{"type":"text","content":"EOM filed an IND application for the treatment of cachectic cancer patients at the FDA’s Office of Cardiology, Hematology, Endocrinology and Nephrology Diseases (OCHEND) to conduct an o...